Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, avinza™, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain

Journal of Pain and Symptom Management

Volumn 23, Issue 4, 2002, Pages 292-300

  Portenoy, Russell K ^a   Sciberras, Andréa ^a   Eliot, Lise ^b   Loewen, Gordon ^b   Butler, Jackie ^c   Devane, John ^c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

^c ELAN PHARMACEUTICALS   (United States)

Author keywords

Chronic pain; Morphine sulfate; Pharmacodynamics; Pharmacokinetics; Sustained release formulations

Indexed keywords

CONTIN; MORPHELAN; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MORPHINE SULFATE; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EDEMA; FEMALE; FLATULENCE; HUMAN; HYPERGLYCEMIA; INSOMNIA; MALE; NAUSEA; PAIN; PROTEINURIA; RASH; SINUSITIS; SOMNOLENCE; STATISTICAL ANALYSIS; STEADY STATE; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; ANALGESICS, OPIOID; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; PAIN; PAIN MEASUREMENT;

EID: 0036242239     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(02)00382-2     Document Type: Article

References (13)

1. Trends in medical use and abuse of opioid analgesics
2. New strategies in opioid therapy for cancer pain
3. Opioid therapy for chronic nonmalignant pain: Clinician's perspective
4. A patient preference study comparing two extended-release morphine sulfate formulations (once-daily Kadian® versus twice-daily MS Contin®) for cancer pain
5. Analgesic response to single and multiple doses of controlled-release morphine tablets and morphine oral solution in cancer patients
6. Steady-state pharmacokinetic comparison of Morphelan™ ROER™ (Morphine Sulfate Rapid Onset Extended Release) once-a-day and morphine oral solution administered q4h around-the-clock in healthy volunteers
7. Sustained relief of chronic pain: Pharmacokinetics of sustained release morphine
8. A comparison of Kapanol (a new sustained- release morphine formulation), MST Continus, and morphine solution in cancer patients: Pharmacokinetics aspects of morphine and morphine metabolites
9. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain
10. Pharmacokinetic-pharmacodynamic relationship of morphine and metabolites after oral administration of Morphelan™ or MS Contin® in patients with chronic, moderate-to-severe pain of non-malignant origin
11. Breakthrough pain: Definition, prevalence and characteristics
12. Efficacy of a new once-daily, rapid-onset, extended-release morphine sulfate formulation (Morphelan™ ROER™) and a twice-daily morphine sulfate controlled-release formulation (MS Contin®) in patients with chronic moderate-to-severe osteoarthritis pain